MD, PhD, MAE, FMedSci, FRCP, FRCPEd.

The Japanese physician and immunologist Shimon Sakaguchi, the American immunologist Fred Ramsdell and the American molecular biologist Mary Brunkow have been awarded this year’s Nobel Prize in Medicine. The work of the three researchers has completely changed our understanding of the immune system.

In 1995, Shimon Sakaguchi discovered a previously unknown type of immune cell, the Regulatory T cell (Treg). The immune system’s T cells are like an army, trained to kill invaders. The thymus eliminates any rogue T cells that might attack the body’s own cells—a process called “central tolerance.” But why then do some of us still develope autoimmune diseases?

Sakaguchi showed there was a second layer of protection outside the thymus. The Tregs act as brakes or peacekeepers, actively moving around the body to suppress other immune cells that get confused and mistakenly try to attack the body’s own organs.

In 2001, Mary Brunkow and Fred Ramsdell were studying a strain of mice that suffered from a severe, fatal autoimmune disorder. They managed to identify the exact genetic defect responsible for the disease: a mutation in a previously unknown gene they named Foxp3. They then found that a mutation in the human version of this gene also causes a severe, rare autoimmune disorder called IPEX syndrome. The broken Foxp3 gene meant the immune system started attacking the body. In other words, the Foxp3 gene was a master control switch for immune regulation.

Two years later, Sakaguchi was able to link the two discoveries by showing that the Foxp3 gene found by Brunkow and Ramsdell is the master switch that controls the development and function of the Regulatory T cells Tregs, which he had discovered.

The three Nobel laureats essentially demonstrated that, if you have properly functioning Tregs, thanks to a healthy Foxp3 gene, your immune system maintains peace or “self-tolerance”. If this system breaks down, your immune system turns on you, causing autoimmune disease. Their collective work created the field of peripheral immune tolerance and forms the basis for developing new treatments for conditions such as autoimmune diseases, cancer immunotherapy and organ transplantation.

8 Responses to Nobel Prize for 3 scientists who discovered that “Regulatory T cells are the immune system’s ‘security guards’ that prevent immune cells from attacking our own body”

  • So yet another year in which a Nobel prize is not won for homeopathy.

  • Actual science in action and well deserved. I reckon RFK jr will ignore this for precisely these reasons.

  • makes me wonder how the alt- med folks who “do their own research” are reacting……

    • they will soon claim that their SCAMs affect TRegs, I suppose.

    • From 20 years ago:

      The Stage Has Been Set: Treg Cell Essentiality to the Immune System and CAM

      The wealth of cutting-edge knowledge of Treg cell function in immune system-related disorders, coupled with substantial evidence of natural immune system modifiers, makes this cell an excellent target for investigation and application by CAM researchers. We now have a solid basis for delving into the specifics of Treg cell action in the pathology of disease and exploring the use of Treg cells as a therapeutic target in the treatment of hypersensitivity, cancer, infection, autoimmunity and organ transplant facilitation. Already at the molecular level Ventura [58 60] has proposed that

      ‘CAM modalities may deeply affect both the signaling and transcriptional level of cellular homeostasis. Such a perception holds promises for a new era in CAM, prompting reproducible documentation of biological responses to CAM-related strategies and compounds. To this end, functional genomics and proteomics and the comprehension of the cell signaling networks may substantially contribute to the development of a molecular evidence-based CAM’.

      Vojdani A, Erde J. Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I). Evid Based Complement Alternat Med. 2006 Mar;3(1):25–30. doi:10.1093/ecam/nek022. Epub 2006 Feb 7.
      PMID: 16550220; PMCID: PMC1375245.

      Reference 60:
      Ventura C. CAM and cell fate targeting: molecular and energetic insights into cell growth and differentiation. Evid Based Complement Alternat Med. 2005 Sep;2(3):277-83. doi:10.1093/ecam/neh100. Epub 2005 Jul 20.
      PMID: 16136206; PMCID: PMC1193541.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Subscribe via email

Enter your email address to receive notifications of new blog posts by email.

Recent Comments

Note that comments can be edited for up to five minutes after they are first submitted but you must tick the box: “Save my name, email, and website in this browser for the next time I comment.”

The most recent comments from all posts can be seen here.

Archives
Categories